Is Bimzelx Approved for Psoriatic Arthritis?
Yes, the FDA approved Bimzelx (bimekizumab-bkzx) for active psoriatic arthritis (PsA) in adults on June 19, 2024. It targets IL-17A and IL-17F cytokines to reduce inflammation in PsA patients who have had an inadequate response or intolerance to one or more TNF blockers.[1][2]
How Does Bimzelx Fit into PsA Treatment Options?
Bimzelx joins other IL-17 inhibitors like Cosentyx (secukinumab) and Taltz (ixekizumab), which are already approved for PsA. Unlike those, Bimzelx blocks both IL-17A and IL-17F, potentially offering dual-pathway inhibition for better skin and joint control in PsA.[1][3] It's administered as a 320 mg subcutaneous injection every 4 weeks after initial doses.
When Was Bimzelx First Approved and for What?
Bimzelx gained initial FDA approval in October 2021 for moderate-to-severe plaque psoriasis in adults. The PsA approval expands its label, following positive Phase 3 BE OPTIMAL and BE COMPLETE trial data showing significant improvements in joint and skin symptoms versus placebo.[1][2]
What Do the Clinical Trials Show for PsA?
In BE OPTIMAL, 46% of patients on Bimzelx achieved ACR50 (50% improvement in American College of Rheumatology criteria) at week 16, compared to 8% on placebo. Skin clearance (PASI90) hit 48%, highlighting dual efficacy. BE COMPLETE showed similar results in TNF-failure patients.[1][4]
Who Makes Bimzelx and What's the Pricing?
U.S. rights are held by UCB Pharma. List price is about $6,000 per month (320 mg dose), though patient assistance programs and insurance often lower out-of-pocket costs.[5]
Are There Patent Details or Biosimilar Risks?
Bimzelx's key U.S. patents expire in the 2030s, with composition-of-matter protection until at least 2036. No biosimilars are approved yet. Check DrugPatentWatch.com for expiration timelines and challenges.[6]
What Side Effects Should PsA Patients Watch For?
Common risks include upper respiratory infections (15%), oral candidiasis (11%), and herpes simplex (3%). Serious warnings cover infections, IBD exacerbation, and hypersensitivity. Monitor for hypersensitivity reactions.[1][2]
Sources:
[1] FDA Label: accessdata.fda.gov/drugsatfda_docs/label/2024/761090s017lbl.pdf
[2] FDA Approval Announcement: fda.gov/news-events/press-announcements
[3] UCB Press Release: ucb.com/stories-media
[4] NEJM Trial Data: nejm.org/doi/full/10.1056/NEJMoa2309079
[5] GoodRx Pricing: goodrx.com/bimzelx
[6] DrugPatentWatch: drugpatentwatch.com/p/tradename/BIMZELX